CMTM6 enables PD-L1-expressing cancer cells to escape T cell-mediated anti-tumor immunity, whereas CMTM6 depletion significantly reduces the protein expression of PD-L1 and alleviates the suppression of tumor-specific T-cell activity.58,59 Thus, targeting these deubiquitinases or protein adaptors is believed to enhance the efficacy of immunotherapy by facilitating PD-L1 protein degradation. Here, CD274 is linked to cancer.